COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study-Reference-Cited by-同舟云学术

COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study

Published:2018-09-04 Issue:1 Volume:16 Page:
ISSN:1477-9560
Container-title:Thrombosis Journal
language:en
Short-container-title:Thrombosis J

Author:

Cohen Alexander T., ,Maraveyas Anthony,Beyer-Westendorf Jan,Lee Agnes Y. Y.,Mantovani Lorenzo G.,Bach Miriam

Funder

Bayer

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1186/s12959-018-0176-2.pdf

Reference52 articles.

1. Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117:219–30.

2. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001275.

3. Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost. 2017;117:57–65.

4. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–4.

5. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–8.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Care pathways for patients with cancer-associated thrombosis: From diagnosis to long-term follow-up;Archives of Cardiovascular Diseases;2024-01

2. Comparison of important factors to patients recovering from pulmonary embolism and items covered in patient-reported outcome measures: A mixed-methods systematic review;Thrombosis Research;2024-01

3. Cancer‐associated thrombosis and drug–drug interactions of antithrombotic and antineoplastic agents;Cancer;2023-07-04

4. Safety and Efficacy of Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Pediatric Oncology Patients;Journal of Pediatric Hematology/Oncology;2022-09-19

5. DOACs or VKAs or LMWH – What is the optimal regimen for cancer-associated venous thromboembolism? A systematic review and meta-analysis;Annals of Medicine & Surgery;2022-07